Large pipeline and new safety issues likely to change 1st line recommendations for multiple sclerosis

Abstract

ABSTRACT Multiple Sclerosis (MS) is chronic neurodegenerative disorder which can result in significant morbidity. Currently, there are not evidence-based guidelines for the choice of which first-line agent to start with, when to switch, or what to switch to, when treating MS. This review article discusses recent changes related to the treatment of MS and reviews disease modifying therapies in the pipeline for treatment of relapsing-remitting multiple sclerosis.